25 Startups Transforming The Weight-Loss Landscape

Chasing the Lucrative $100 Billion Weight-Loss Drugs Market: Startups in the Race

Photo by sydney Rae on Unsplash

Barclays predicts that the obesity drug industry could reach a staggering value of $200 billion within the coming decade.

However, despite the significant growth potential, patients continue to encounter challenges when it comes to accessing GLP-1 drugs for weight loss. The use of telemedicine platforms, priced at around $100 to $140 per month, often does not include coverage for the expenses associated with these drugs. This limited coverage can be attributed to the prevailing perception of obesity as primarily an aesthetic concern rather than a medical condition. Consequently, patients are left with the burden of out-of-pocket expenses that can surpass $1,000 monthly.

These obstacles highlight the disparity between the industry's projected value and the current hurdles faced by patients in need of effective weight-loss treatments

I showcase 25 emerging startups that are transforming the field of weight loss.

Category Breakdown

Digital Platforms providing medication and support with a single focus on weight loss:

• Found: US / Funding $132M

• Calibrate: US / Funding $125M

• Sequence acquired by Weight Watchers: US

• Weekend Health acquired by Weight Watchers: US

Telehealth companies also providing other solutions such as sexual health, mental health, fertility, hair loss, etc:

• Everly Health: US / Funding $200M

• Noom: US / Funding $659M

• Ro: US / Funding $1B

• One Medical: US / Funding $532M / NASDAQ

Virtual Clinics providing clinical consultation, advice and treatment planning:

• FormHealth: US / Funding $26.3M

• Fella: US / Funding N/A

• Enara: US / Funding $9M

• Alfie: US / Funding N/A

• Knownwel: US / Funding $4.5M

• Accomplish Health: US / Funding N/A

Companies focusing on CGM, Metabolic Health and others ways of weight Management:

• Signos: US / Funding $17M

• Oviva: US / Funding $113M

• Equip: US / Funding $75M

• Limbo: US / Funding $6M

• Viome: US / Funding $169.5M

• Heal Club: US / Funding N/A

• Nextmed: US / Funding N/A

• Ilant Health: US / Funding N/A

• Virta: US / Funding $373M

• Fruit Street: US / Funding $15.5M

• Intelli health: US / Funding N/A

Barclays' valuation call stands as one of the most audacious for the industry, with Citi Pharmaceuticals estimating a $50 billion valuation by 2030, and Morgan Stanley similarly projecting a $54 billion valuation by 2030 in a research note from last August.

Undoubtedly, this is a market that cannot be overlooked.

+ endurance is good,

Martin